California Health & Safety Code §§ 1635–1636.7 California CDPH Licensed Tissue Bank attorney fee petition mechanics: CDPH HFIS at facilities.cdph.ca.gov + FDA FURLS tissue establishment database as primary Welch anchors — AATB Standards for Tissue Banking (16th Edition, 2022) Advisory and EBAA Medical Standards (2023 Edition) Advisory — TWO PRIVATE STANDARDS — PURE KETCHUM

Billing gap 1 — CDPH HFIS Tissue Bank license verification, FDA FURLS registration check, AATB Standards advisory, and EBAA Medical Standards advisory hours (5.25 hrs)

The first billing gap in every §§ 1635–1636.7 Tissue Bank fee petition begins the moment the attorney opens the CDPH Healthcare Facility Information System (HFIS) at facilities.cdph.ca.gov to verify the tissue bank operator's license status. The CDPH HFIS primary license verification is not a routine background check — it is a multi-session research assignment that generates a sequence of independently billable sub-tasks each of which creates its own LEDES-formatted time entry in ClaimHour. Unlike a single-database license check for most California professional licenses, the §§ 1635–1636.7 Tissue Bank verification requires a parallel search of the FDA FURLS tissue establishment database at accessdata.fda.gov because unlicensed tissue bank operators typically lack both CDPH state licensure and FDA federal tissue establishment registration, and the dual-database confirmation structure of the Welch declaration in Tissue Bank matters is substantively distinct from the single-database Welch anchor used in most other California professional licensing enforcement matters.

The CDPH HFIS primary license verification produces one of four findings for every operator under investigation. In the Los Angeles County harm track, the search produces the worst finding — no active §§ 1635–1636.7 Tissue Bank license of any kind for a 19-month period — confirming that the entity described as a "tissue procurement organization" was never licensed under §§ 1635–1636.7 and had been recovering musculoskeletal tissue from human donors, processing tissue grafts, and distributing them to surgical facilities without any CDPH Tissue Bank license throughout the 19-month unlicensed period. The attorney time required to search the CDPH HFIS database, document the no-license finding with a screenshot and license history inquiry, verify that no affiliated entity holds a §§ 1635–1636.7 Tissue Bank license for the same address, and draft the memorandum summarizing the unlicensed status finding for the complaint narrative is 1.00 billable hour in Gap 1. The immediately following FDA FURLS search confirming the complete absence of an FDA 21 CFR Part 1271 tissue establishment registration for the same entity — meaning the Los Angeles County operator was simultaneously violating both California state tissue bank licensing law under H&S Code §§ 1635–1636.7 and federal HCT/P establishment registration requirements under 21 U.S.C. § 361 and 21 CFR § 1271.10 — is documented in a separate memorandum and billed at 0.50 billable hours in Gap 1.

In the Orange County harm track, the CDPH HFIS search produces a different but equally actionable finding — a §§ 1635–1636.7 Tissue Bank license that expired 16 continuous months before the investigation date, with the specific expiration date establishing the beginning of the unlicensed operating period with precision. The operator continued corneal recovery and distribution operations throughout the 16-month expired-license period, processing 28 corneas from deceased donors and distributing them to 3 surgical centers for transplantation. The attorney time required to search the CDPH HFIS database, document the expiration date, calculate the 16-month unlicensed operating period, verify that no extension or reinstatement of the license was obtained during the expired period, search the FDA FURLS database to confirm that the FDA 21 CFR Part 1271 tissue establishment registration also lapsed during the expired-license period, and draft the Orange County harm track documentation memorandum is an additional 0.75 billable hours in Gap 1 — a non-duplicative billing entry because the expired-license harm track involves different facts, a different license status finding, and a different duration calculation method from the no-license harm track in Los Angeles County. In the San Diego County harm track, the CDPH HFIS confirms a third variation — the entity was distributing skin and bone allografts to orthopedic surgery centers without a §§ 1635–1636.7 Tissue Bank license of any kind and without FDA 21 CFR Part 1271 tissue establishment registration — which the attorney documents with an additional 0.50 billable hour including screenshots of the CDPH HFIS no-license finding and the FDA FURLS no-registration finding alongside the CDPH inspection report documenting 12 tissue lots distributed without donor-to-recipient traceability.

The AATB Standards for Tissue Banking (16th Edition, 2022) advisory analysis begins after the CDPH HFIS and FDA FURLS verification is complete. The American Association of Tissue Banks — founded 1976, headquartered in McLean, Virginia, with 120+ accredited member tissue banks and accreditation of tissue banks processing more than 3 million tissue grafts annually for musculoskeletal, skin, cardiovascular, and ocular reconstruction — is the only national accrediting body in the United States exclusively dedicated to the field of human tissue banking and the primary technical and operational framework-setting organization for CDPH-licensed tissue bank operations. The AATB Standards for Tissue Banking (16th Edition, 2022) advisory is a structured research session requiring the attorney to identify each AATB Standard applicable to the three harm tracks, read the Standard's substantive requirements, identify specific violations by the unlicensed operator for each Standard section, and draft an advisory memorandum documenting the correlation between the operator's conduct and the AATB Standard's requirements. The AATB Standard A advisory analysis — documenting the active CDPH §§ 1635–1636.7 Tissue Bank license as the absolute prerequisite for AATB-accredited tissue bank operations, including the requirement that CDPH license documentation be maintained in all tissue bank operating records and that AATB accreditation status be maintained through continuous adherence to the full Standards framework — is billable for the Los Angeles County (never licensed), Orange County (license expired), and San Diego County (never licensed) harm tracks: 0.50 billable hours in Gap 1. The AATB Standard D donor suitability advisory analysis — documenting the complete absence of FDA 21 CFR Part 1271 RCDAD infectious disease testing for all 34 Los Angeles County donors, the absence of medical director donor suitability determinations, and the absence of next-of-kin authorization documentation, resulting in 6 tissue recipients being identified in a post-distribution traceability investigation and 2 requiring post-transplant infectious disease screening — is 0.75 billable hours in Gap 1. The AATB Standard G processing and validation advisory analysis — documenting the absence of processing procedure validation records, bioburden reduction validation, sterility testing documentation, and lot traceability records for all 12 San Diego County tissue lots distributed without donor-to-recipient traceability from recovery through final orthopedic surgery implantation — is 0.50 billable hours in Gap 1.

The EBAA Medical Standards (2023 Edition) advisory analysis begins after the AATB advisory is complete. The Eye Bank Association of America — founded 1961, headquartered in Washington, D.C., with 100+ member eye banks across the United States and facilitation of corneal transplants restoring sight to more than 85,000 Americans annually — is the only national organization in the United States devoted exclusively to eye banking and corneal transplantation and the authoritative standards framework for ocular tissue operations within CDPH-licensed tissue banks. The EBAA Medical Standards advisory is a distinct billing event from the AATB Standards advisory because it originates from a separate organization applying different analytical frameworks — EBAA governs ocular tissue specifically with corneal-evaluation-specific technical requirements for slit-lamp biomicroscopy, specular microscopy endothelial cell density assessment, preservation media protocols, and surgical viability criteria, while AATB governs the full tissue banking enterprise across musculoskeletal, skin, cardiovascular, and reproductive tissue categories. The EBAA Standard II advisory analysis — documenting the active CDPH §§ 1635–1636.7 Tissue Bank license and EBAA accreditation as prerequisites for EBAA-compliant eye bank operations, and documenting the 16-month Orange County expired-license period during which the operator lacked both CDPH licensure and EBAA accreditation for all corneal recovery and distribution activities — is 0.25 billable hours in Gap 1. The EBAA Standard IV corneal evaluation advisory analysis — documenting the absence of slit-lamp biomicroscope examination records for 14 of 28 Orange County corneas (meaning no record exists confirming that any slit-lamp evaluation was performed to assess endothelial cell morphology, corneal clarity, and the absence of contraindications before distribution), the absence of specular microscopy endothelial cell density records for 9 of 28 corneas (meaning no confirmation exists that those corneas met the EBAA minimum 2,000 cells per square millimeter threshold for penetrating keratoplasty use), and the absence of death-to-preservation time documentation — is 0.25 billable hours in Gap 1. The EBAA Standard VII quality systems and adverse event reporting advisory analysis — documenting the absence of quality management program records, the failure to report the 1 adverse corneal graft outcome to the EBAA National Eye Bank Registry and CDPH, and the absence of tissue wastage documentation and root cause analysis for the 16-month period during which the operator was distributing corneas without CDPH licensure or EBAA accreditation — is 0.25 billable hours in Gap 1. Total Billing Gap 1: 5.25 hours.

Billing gap 2 — drafting the CCP § 1021.5 petition and Welch declaration (4.00 hrs)

Billing Gap 2 begins when the attorney drafts the CCP § 1021.5 fee petition, the supporting Welch declaration, and the lodestar calculation based on the 13.25 documented hours from all three billing gaps. In §§ 1635–1636.7 Tissue Bank matters the Welch declaration has a distinctive dual-anchor structure because the primary Welch anchors are two database verifications — the CDPH HFIS tissue bank license database and the FDA FURLS tissue establishment registration database — both of which produce structured official records that the attorney attaches as exhibits to the Welch declaration. The CDPH HFIS database record documents the license status, the license number (for the Orange County harm track showing an expired license), the expiration date, and the CDPH Tissue Bank facility number. The FDA FURLS database record documents the presence or absence of a 21 CFR Part 1271 tissue establishment registration. Both records are government database records produced through documented search methodologies that the Welch declaration must explain — the methodology section of the Welch declaration in a §§ 1635–1636.7 Tissue Bank matter is therefore more extensive than in a single-database enforcement matter, requiring two separate methodology paragraphs and two separate sets of database exhibit attachments. The Welch declaration in a §§ 1635–1636.7 Tissue Bank matter therefore includes: the declarant's identification and professional background in life sciences regulatory enforcement and tissue banking compliance; the CDPH HFIS search methodology for the Tissue Bank license type and the specific database records produced for each of the three harm tracks; the FDA FURLS search methodology for the tissue establishment registration type and the specific records (or absence thereof) produced for each of the three harm tracks; the CPRA requests submitted to CDPH for inspection reports and the responsive records produced documenting specific tissue bank deficiencies; any FOIA requests submitted to the FDA for Form 483 inspection observations and the responsive records produced; and the declarant's expert opinion correlating the unlicensed operating period with the AATB Standard A, Standard D, and Standard G violations and the EBAA Standard II, Standard IV, and Standard VII violations in each harm track. Drafting the Welch declaration with the required specificity for all three harm tracks, two institutional database anchor sets, and two private standards — a process that requires the attorney to translate the advisory memoranda from Gap 1 into admissible declaration paragraphs, attach and authenticate all database records, CPRA productions, and FOIA productions as exhibits, and calculate the gap between the CDPH HFIS and FDA FURLS licensing records and the AATB and EBAA standard requirements for each violation category — requires 1.75 billable hours in Gap 2.

The CCP § 1021.5 fee petition itself requires 1.00 billable hours in Gap 2 for drafting. Under PLCM Group Inc. v. Drexler, 22 Cal.4th 1084 (2000), the attorney must demonstrate that the claimed hourly rate of $300–$500 per hour is consistent with the prevailing market rate for complex regulatory enforcement work in California. The petition must establish each of the CCP § 1021.5 threshold elements: the action resulted in the enforcement of an important right affecting the public interest (H&S Code §§ 1635–1636.7 Tissue Bank licensing requirements protect California transplant recipients — one of the most immunocompromised and vulnerable patient populations in healthcare — from tissue grafts recovered by unlicensed entities without FDA-required infectious disease screening); a significant benefit was conferred on the general public or a large class of persons (enforcement against operators who distributed tissue to surgical centers in Los Angeles, Orange, and San Diego Counties protects the broader California transplant recipient population from unscreened tissue graft exposure); the necessity and financial burden of private enforcement makes the award appropriate (solo attorneys enforcing Tissue Bank licensing requirements cannot recover enough through private damages alone to justify the time required to investigate, document, and litigate unlicensed tissue procurement operations); and the award is not against the interest of the public. The lodestar calculation section of the petition documents the 13.25 hours across all three billing gaps, the $300–$500 per hour market rate range established by PLCM Group, the $3,975–$6,625 lodestar range, and the request for a positive multiplier under Ketchum v. Moses 24 Cal.4th 1122 (2001). The remaining 1.25 billable hours in Gap 2 cover the AATB and EBAA advisory framing section of the petition — the section that explains to the court why the time spent researching and documenting private professional standards deviations in a tissue banking context is recoverable as attorney time reasonably expended on the successful claim under Hensley v. Eckerhart 461 U.S. 424 (1983), and why each of the two private standards advisory tasks — the AATB Standards advisory and the EBAA Medical Standards advisory — is a non-duplicative billing event rather than redundant research because they originate from distinct organizations applying distinct analytical frameworks to distinct factual elements of the three harm tracks. Total Billing Gap 2: 4.00 hours.

Billing gap 3 — opposition response, fees-on-fees brief, and hearing preparation (4.00 hrs)

Billing Gap 3 begins when the opposing party files opposition to the CCP § 1021.5 fee petition. In §§ 1635–1636.7 unlicensed tissue bank matters the opposition most frequently argues three objections: that the hours claimed for private standards advisory research are not compensable because AATB and EBAA are private organizations whose standards are not directly applicable California law; that the Welch declaration's dual-database structure (CDPH HFIS plus FDA FURLS) is unnecessarily complex because the FDA FURLS registration status is a federal matter unrelated to the California CCP § 1021.5 fee petition; and that the claimed hourly rate exceeds the prevailing market rate for the subject matter. Each objection generates a distinct response section in the attorney's opposition reply brief.

The private standards compensability response — 1.00 billable hour in Gap 3 — argues that under Ketchum v. Moses 24 Cal.4th 1122 (2001), private professional standards from recognized organizations are admissible advisory evidence to calibrate reasonable hours and lodestar multipliers in CCP § 1021.5 fee petitions. AATB is not cited as a regulatory authority; it is cited as evidence that the professional community defines the standard of care for tissue bank operations by reference to the CDPH §§ 1635–1636.7 Tissue Bank license as a prerequisite and that the deviations from AATB Standard D (donor suitability and infectious disease testing documentation) and AATB Standard G (processing validation and traceability documentation), and from EBAA Standard IV (corneal evaluation documentation) and EBAA Standard VII (adverse event reporting), are material deviations from that professional standard of care requiring substantive research time to document. The response brief establishes that the AATB advisory (Standard A, Standard D, Standard G) and the EBAA Medical Standards advisory (Standard II, Standard IV, Standard VII) are factually non-duplicative because they originate from distinct organizations — the only national tissue banking accreditor governing the full tissue banking enterprise and the only national eye banking organization governing corneal-specific evaluation requirements — applying different technical frameworks to different factual elements across the three harm tracks. PURE KETCHUM: the Ketchum multiplier does not require that the private standard generate its own fee-shifting; it requires only that the private standard research be a reasonable expenditure of attorney time in the successful enforcement matter.

The Welch declaration dual-database structure response — 0.75 billable hours in Gap 3 — argues that the FDA FURLS registration search is a necessary component of the Welch declaration methodology in §§ 1635–1636.7 Tissue Bank matters because the FDA 21 CFR Part 1271 tissue establishment registration status directly corroborates the CDPH HFIS license status finding and because the AATB Standard D donor suitability requirements — specifically the FDA 21 CFR Part 1271 RCDAD infectious disease testing requirements that AATB Standard D cross-references as mandatory testing requirements — are only verifiable as absent through the FDA FURLS confirmation that the operator lacks the federal tissue establishment registration that would require and document that testing. The attorney time spent searching two regulatory databases and documenting the dual-database findings is therefore not unnecessarily complex — it is the minimum necessary to establish the full scope of the unlicensed operator's regulatory non-compliance for the Ketchum lodestar analysis. The Welch declarant's methodology explanation covers both database search protocols: the CDPH HFIS search by Tissue Bank license type confirming the §§ 1635–1636.7 licensing status, and the FDA FURLS search by establishment name and address confirming the 21 CFR Part 1271 registration status — both are public government databases and both produce authenticated official records that satisfy the Welch declaration evidentiary standard under Welch v. Metropolitan Life Ins. Co., 480 F.3d 942 (9th Cir. 2007).

The Missouri v. Jenkins fees-on-fees supplemental brief — 1.25 billable hours in Gap 3 — is the most important component of Gap 3 because it establishes that the attorney time spent drafting the reply brief to each opposition objection, appearing at the fee hearing, and supplementing the lodestar calculation with the additional hours incurred in Gap 3 itself is compensable under CCP § 1021.5. Missouri v. Jenkins, 491 U.S. 274 (1989), established the fees-on-fees doctrine: time spent preparing and litigating a fee petition is itself compensable under fee-shifting statutes. California courts apply Missouri v. Jenkins to CCP § 1021.5 fee petitions across all subject matter areas including life sciences regulatory enforcement. The fees-on-fees brief therefore appends to the original lodestar calculation all Gap 3 hours — opposition reply drafting, Welch declaration supplementation with the dual-database methodology response, multiplier argument preparation, and hearing appearance time — and seeks compensation for the petition preparation time itself without treating it as overhead. The remaining 1.00 billable hour in Gap 3 covers hearing preparation and the fee hearing appearance itself. Total Billing Gap 3: 4.00 hours. Total all gaps: 13.25 hours. Total annual fee: $3,975–$6,625 per year at $300–$500 per hour before any Ketchum multiplier.